Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) CEO Sells 128,127 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum sold 128,127 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $58.27, for a total value of $7,465,960.29. Following the completion of the sale, the chief executive officer now directly owns 97,687 shares of the company’s stock, valued at $5,692,221.49. The trade was a 56.74 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Andrew Dudum also recently made the following trade(s):

• On Friday, January 31st, Andrew Dudum sold 100,000 shares of Hims & Hers Health stock. The stock was sold at an average price of $35.22, for a total value of $3,522,000.00.
• On Thursday, January 23rd, Andrew Dudum sold 27,098 shares of Hims & Hers Health stock. The stock was sold at an average price of $30.08, for a total value of $815,107.84.
• On Tuesday, January 21st, Andrew Dudum sold 300 shares of Hims & Hers Health stock. The stock was sold at an average price of $30.00, for a total value of $9,000.00.
• On Thursday, January 16th, Andrew Dudum sold 36,460 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.09, for a total value of $987,701.40.
• On Monday, December 16th, Andrew Dudum sold 78,127 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.62, for a total value of $2,314,121.74.
• On Monday, December 2nd, Andrew Dudum sold 33,513 shares of Hims & Hers Health stock. The stock was sold at an average price of $33.38, for a total value of $1,118,663.94.

Hims & Hers Health Stock Down 26.1 %

Shares of Hims & Hers Health stock opened at $49.10 on Friday. Hims & Hers Health, Inc. has a twelve month low of $9.25 and a twelve month high of $72.98. The business has a 50-day moving average price of $35.05 and a 200 day moving average price of $25.76. The firm has a market cap of $10.73 billion, a PE ratio of 111.58 and a beta of 1.35.

Hedge Funds Weigh In On Hims & Hers Health

Several institutional investors and hedge funds have recently modified their holdings of HIMS. CWM LLC increased its stake in shares of Hims & Hers Health by 21.4% in the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after purchasing an additional 1,054 shares in the last quarter. Creative Planning boosted its holdings in Hims & Hers Health by 18.1% in the 3rd quarter. Creative Planning now owns 25,925 shares of the company’s stock worth $478,000 after buying an additional 3,979 shares during the last quarter. Venture Visionary Partners LLC acquired a new stake in Hims & Hers Health in the 3rd quarter worth about $238,000. Lake Street Private Wealth LLC boosted its holdings in Hims & Hers Health by 80.3% in the 3rd quarter. Lake Street Private Wealth LLC now owns 103,447 shares of the company’s stock worth $1,905,000 after buying an additional 46,076 shares during the last quarter. Finally, International Assets Investment Management LLC acquired a new stake in Hims & Hers Health in the 3rd quarter worth about $6,790,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. BTIG Research assumed coverage on Hims & Hers Health in a research note on Tuesday, January 7th. They issued a “buy” rating and a $35.00 target price for the company. Citigroup lowered Hims & Hers Health from a “neutral” rating to a “sell” rating and raised their target price for the stock from $24.00 to $25.00 in a research note on Friday, January 10th. Morgan Stanley lowered Hims & Hers Health from an “overweight” rating to an “equal weight” rating and raised their target price for the stock from $42.00 to $60.00 in a research note on Tuesday, February 18th. Needham & Company LLC raised their target price on Hims & Hers Health from $28.00 to $31.00 and gave the stock a “buy” rating in a research note on Monday, January 6th. Finally, Deutsche Bank Aktiengesellschaft raised their target price on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, November 6th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $28.53.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.